Abstract
Purpose of Review
Autoimmune hepatitis (AIH) is a chronic progressive autoinflammatory disease of the liver caused by the dysregulation of an individual’s immune response. As discovery in science and innovation in clinical care have been reported, we look to summarize the most up-to-date clinical advances and management strategies in pediatric AIH.
Recent Findings
Discovery related to genetic predisposition, epigenetic modification, and environmental triggers has been implicated in the etiopathogenesis of AIH and enabled a greater understanding of the disease and its management. Still, diagnosis in children is dependent on adult-derived scoring systems that are invasive and imperfect. Treatment regimens with immunosuppressive agents have been well established and initial responses are generally favorable. However, side effects can be significant, medication titration can be variable, and relapses are common. Medication intolerant or refractory cases present unique challenges in both prognosis and alternative therapeutic opportunities.
Summary
In children, improvements in strategies that encompass diagnostic and prognostic tools to optimize care and predict outcomes, as well as establishing learning health network approaches to care constitute areas of ongoing and future discovery.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Mack CL, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases. Hepatology. 2020;72(2):671–722. The objectives of this document are to provide guidance in the diagnosis and management of autoimmune hepatitis (AIH) based on current evidence and expert opinion and to present guidelines to clinically relevant questions based on systematic reviews of the literature and the quality of evidence. This practice guideline/guidance constitutes an update of the guidelines on AIH published in 2010 by the American Association for the Study of Liver Diseases (AASLD). It updates the epidemiology, diagnosis, management, and outcomes of AIH in adults and children.
Mieli-Vergani G, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr. 2018;66(2):345–60.
Tunio NA, et al. Epidemiology of autoimmune hepatitis (AIH) in the United States between 2014 and 2019: a population-based national study. J Clin Gastroenterol. 2021;55(10):903–10.
Kemme S, Mack CL. Pediatric autoimmune liver diseases: autoimmune hepatitis and primary sclerosing cholangitis. Pediatr Clin North Am. 2021;68(6):1293–307.
Gatselis NK, et al. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol. 2015;21(1):60–83.
Sirbe C, et al. Pathogenesis of autoimmune hepatitis-cellular and molecular mechanisms. Int J Mol Sci. 2021;22(24):13578.
Engel B, et al. Genetic aspects of adult and pediatric autoimmune hepatitis: a concise review. Eur J Med Genet. 2021;64(6):104214.
Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmmune hepatitis. Cell Mol Immunol. 2022;19(2):158–76.
Vergani D, Terziroli Beretta-Piccoli B, Mieli-Vergani G. A reasoned approach to the treatment of autoimmune hepatitis. Dig Liver Dis. 2021;53(11):1381–93.
Ma Y, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35(3):658–64.
Sebode M, et al. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance. Front Immunol. 2018;9:609.
Lapierre P, et al. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology. 1999;116(3):643–9.
Mieli-Vergani G, Vergani D. Autoimmune hepatitis in childhood. Clin Liver Dis (Hoboken). 2014;3(1):6–8.
Hennes EM, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–76.
Balitzer D, et al. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol. 2017;30(5):773–83.
Galaski J, et al. Update of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing. J Hepatol. 2021;74(2):312–20.
Muratori P, et al. Limitation of the simplified scoring system for the diagnosis of autoimmune hepatitis with acute onset. Liver Int. 2021;41(3):529–34.
Arcos-Machancoses JV, et al. Accuracy of the simplified criteria for autoimmune hepatitis in children: systematic review and decision analysis. J Clin Exp Hepatol. 2019;9(2):147–55.
Wong GW, et al. Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes. Liver Int. 2017;37(3):449–57.
Efe C, et al. Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome and associated extrahepatic autoimmune diseases. Eur J Gastroenterol Hepatol. 2012;24(5):531–4.
Teufel A, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010;44(3):208–13.
Bittencourt PL, et al. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol. 2008;42(3):300–5.
Terziroli Beretta-Piccoli B, Vergani D, Mieli-Vergani G. Autoimmune sclerosing cholangitis: evidence and open questions. J Autoimmun. 2018;95:15–25.
Ricciuto A, et al. Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem? J Hepatol. 2023;70(2):567–75.
Tan CK, et al. Drug-induced autoimmune hepatitis: a minireview. World J Gastroenterol. 2022;28(24):2654–66.
Bjornsson E, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51(6):2040–8.
Deng Q, et al. The emerging epigenetic role of CD8+T cells in autoimmune diseases: a systematic review. Front Immunol. 2019;10:856.
Pecoraro A, et al. Heterogeneity of liver disease in common variable immunodeficiency disorders. Front Immunol. 2020;11:338.
Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: standard treatment and systematic review of alternative treatments. World J Gastroenterol. 2017;23(33):6030–48.
Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7(3):319–33.
Manns MP, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139(4):1198–206.
Woynarowski M, et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr. 2013;163(5):1347-53.e1.
Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology. 2000;119(5):1312–6.
Peiseler M, et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2018;16(2):260-267.e1.
Diaz-Gonzalez A, et al. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration. Hepatology. 2023;77(4):1095–105. Analyzes budesonide use and safety compared to prednisone as 1st line therapy suggesting use is low, generally prescribed in pateitns with milder disease, and provided inferior results.
Sheiko MA, et al. Outcomes in pediatric autoimmune hepatitis and significance of azathioprine metabolites. J Pediatr Gastroenterol Nutr. 2017;65(1):80–5.
Vitfell-Pedersen J, et al. Autoimmune hepatitis in children in Eastern Denmark. J Pediatr Gastroenterol Nutr. 2012;55(4):376–9.
European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004.
Santiago P, et al. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther. 2019;49(7):830–9.
Efe C, et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis. Dig Dis Sci. 2018;63(5):1348–54.
Squires JE, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the diagnosis and management of pediatric acute liver failure. J Pediatr Gastroenterol Nutr. 2022;74(1):138–58.
Narkewicz MR, et al. Prevalence and significance of autoantibodies in children with acute liver failure. J Pediatr Gastroenterol Nutr. 2017;64(2):210–7.
Stravitz RT, et al. Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011;53(2):517–26.
Hartl J, et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol. 2015;62(3):642–6.
Maggiore G, et al. Long-term outcomes of patients with type 1 or 2 autoimmune hepatitis presenting in childhood. J Hepatol. 2023;78(5):979–88.
van Gerven NM, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58(1):141–7.
Harrington C, et al. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology. 2022;76(6):1862–79. This paper is a review of the available literature on potential candidate biomarkers in adult and pediatric AIH.
Elisofon SA, et al. Society of pediatric liver transplantation: current registry status 2011–2018. Pediatr Transplant. 2020;24(1):e13605.
Martin SR, et al. Outcomes in children who underwent transplantation for autoimmune hepatitis. Liver Transpl. 2011;17(4):393–401.
Jossen J, et al. Liver transplantation for children with primary sclerosing cholangitis and autoimmune hepatitis: UNOS database analysis. J Pediatr Gastroenterol Nutr. 2017;64(4):e83–7.
Clancy CM, Margolis PA, Miller M. Collaborative networks for both improvement and research. Pediatrics. 2013;131(Suppl 4):S210–4.
Morrow WR, et al. Outcome of listing for heart transplantation in infants younger than six months: predictors of death and interval to transplantation. The Pediatric Heart Transplantation Study Group. J Heart Lung Transplant. 1997;16(12):1255–66.
Britto MT, et al. Using a network organisational architecture to support the development of Learning Healthcare Systems. BMJ Qual Saf. 2018;27(11):937–46.
Forrest CB, et al. PEDSnet: how a prototype pediatric learning health system is being expanded into a national network. Health Aff (Millwood). 2014;33(7):1171–7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of Interest
Dieudonne Nonga declares no conflict of interest. Maria Amendola declares that she has no conflict of interest. Jordan Serio declares no conflict of interest. Mary Ayers declares that she has no conflict of interest. Amy Taylor declares that she has no conflict of interest. James E. Squires declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Pediatric Gastroenterology
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nonga, D., Amendola, M., Serio, J. et al. Pediatric Autoimmune Hepatitis. Curr Treat Options Peds 9, 106–121 (2023). https://doi.org/10.1007/s40746-023-00271-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40746-023-00271-4